Restasis Isn’t Working: When to Try Something Else

When Your Restasis Stops Working — Or Never Did

You started Restasis because the over-the-counter drops weren’t cutting it anymore. Your eye doctor explained that this one was different — a prescription medication that would actually reduce inflammation and help your eyes produce their own tears over time. You were told it might take three months to feel a difference. You waited it out, applying twice a day, every day.

Maybe it helped a little. Maybe it didn’t help at all. Or maybe it worked for a while and then stopped. Whatever your particular path, you’re now in the position of asking the question that gets surprisingly little honest discussion in eye care: what do you do when prescription dry eye drops don’t actually work?

What Restasis Actually Does (And Doesn’t)

Restasis (cyclosporine 0.05%) is an immunomodulator. It works by suppressing the T-cell-mediated inflammation that drives a particular kind of dry eye — the kind where your immune system is interfering with your lacrimal glands’ ability to produce adequate aqueous (the watery component of tears). When that mechanism is the dominant driver of your dry eye, Restasis can be genuinely effective, increasing tear production measurably over 3–6 months of consistent use.

The trouble is: that mechanism isn’t the dominant driver of dry eye for most patients.

The clinical evidence from the TFOS DEWS II reports and a decade of meibography studies is consistent: roughly 86% of chronic dry eye disease is driven primarily by meibomian gland dysfunction — a problem with the oil layer of your tear film, not the watery layer. In MGD-driven dry eye, your eyes aren’t failing to produce enough tears. They’re producing tears that evaporate too quickly because the meibomian glands at your eyelid margins are obstructed or producing low-quality oil.

Restasis doesn’t address gland obstruction. It doesn’t thermally clear inspissated meibum. It doesn’t kill Demodex mites. It doesn’t address rosacea-driven inflammation at the eyelid margin. If those are the actual problems driving your symptoms, no amount of cyclosporine is going to make a meaningful difference — because cyclosporine is treating a mechanism that isn’t the mechanism that’s broken.

Same Story for Xiidra, Miebo, and the Other Prescription Drops

Restasis isn’t unique here. The same logic applies to Xiidra (lifitegrast) and to the newer prescription options like Miebo (perfluorohexyloctane) and Tyrvaya (varenicline nasal spray). Each of these works through a specific mechanism, addresses a specific subset of dry eye drivers, and produces meaningful improvement in patients whose dry eye is actually driven by that mechanism — and limited improvement in patients whose dry eye is driven by something else.

Xiidra (lifitegrast) blocks the LFA-1/ICAM-1 inflammatory pathway. It works on a different inflammatory mechanism than Restasis but has a similar limitation — it doesn’t address gland obstruction.

Miebo (perfluorohexyloctane) is a fluorinated semifluorinated alkane that forms a stable, evaporation-resistant layer over the tear film. It’s actually one of the more promising newer options for evaporative dry eye specifically — because it directly addresses tear film evaporation, the primary problem in MGD. But it still doesn’t fix the underlying gland obstruction; it manages the downstream effect.

Tyrvaya (varenicline nasal spray) activates the trigeminal parasympathetic nerve pathway to stimulate natural tear production. Like Restasis, it works on aqueous-deficient dry eye and has limited utility in evaporative MGD-driven cases.

None of these is a bad drug. Each is appropriate for specific dry eye mechanisms. The problem is that they’re often prescribed without diagnostic confirmation that the mechanism the drug targets is actually the mechanism driving the patient’s disease.

The Diagnostic Question You Probably Haven’t Been Asked

If you’ve been on prescription dry eye drops for six months or longer without meaningful improvement, the next conversation isn’t “let’s try a different drop.” It’s “what’s actually wrong?”

A real diagnostic dry eye evaluation answers four questions:

What’s your tear production? Schirmer testing tells us whether your lacrimal glands are producing adequate aqueous. Low scores point toward aqueous-deficient dry eye, where drugs like Restasis make sense.
What’s your tear film stability? Tear breakup time measures how quickly your tears evaporate after a blink. Short breakup time points toward evaporative dry eye, where gland-focused treatments matter more than aqueous-stimulating drugs.
What’s the structural state of your meibomian glands? Meibography images the glands directly. Obstruction, truncation, or atrophy on imaging is hard evidence of MGD. You can’t fix what you can’t see.
What’s happening at the eyelid margin? Slit lamp examination identifies Demodex collarettes, lid margin inflammation, telangiectasia (the dilated vessels of rosacea), and other findings that point toward specific drivers.

Most patients arrive at a dry eye specialty consultation having never had any of these specifically evaluated. They’ve had a general eye exam, a refraction, maybe a “your tear film looks dry” assessment — and a prescription. That’s not a diagnostic workup. It’s symptom management without diagnosis.

What Comes After Drops Fail

Once you know what mechanism is actually driving your dry eye, the treatment options expand considerably beyond more prescription drops. For the MGD-driven majority, the most effective treatments target the gland obstruction directly:

IPL therapy — addresses inflammatory drivers, kills Demodex, and helps restore meibomian gland function over a series of treatments.
Radiofrequency therapy — delivers controlled thermal energy deep into the eyelid tissue to melt obstructive meibum and restore oil flow.
Low-level light therapy — photobiomodulation that supports gland recovery and reduces inflammation at the cellular level.
Scleral lenses — for severe and treatment-resistant cases, particularly those driven by aqueous-deficient or autoimmune dry eye, where a saline reservoir over the cornea provides protection no drop can match.

Punctal plugs remain useful for aqueous-deficient cases. Autologous serum tears, made from your own blood serum, can help in select cases with severe corneal involvement. Combined-protocol treatment, which uses multiple modalities together, often produces better results than any single intervention for patients with overlapping mechanisms.

The Bottom Line

If you’ve been on Restasis (or Xiidra, or any prescription dry eye drop) for six months without meaningful improvement, the next step isn’t a different drop — it’s diagnosis. A real comprehensive dry eye evaluation identifies which mechanism is actually driving your symptoms, which determines which treatments will give you durable relief.

Persistent dry eye that hasn’t responded to standard prescription therapy isn’t a sign that you have a hopeless case. It’s almost always a sign that the diagnosis was incomplete and the treatment was targeting the wrong mechanism. That’s a solvable problem — but it requires looking at the disease, not just the symptoms.